Bortezomib — the active ingredient in Velcade and its Indian generic Bortenat 3.5mg — is a cornerstone of myeloma and mantle cell lymphoma treatment in the USA. For oncology teams in Phoenix, Arizona, at Mayo Clinic, Banner MD Anderson, and Dignity Health Cancer Institute, understanding proper dosage and administration of Bortezomib is critical for maximising patient outcomes while minimising toxicity.
Bortenat 3.5mg is supplied as a lyophilised powder for reconstitution, given either subcutaneously (SC) or intravenously (IV). Phoenix oncologists now predominantly use the subcutaneous route, which produces equivalent tumour response rates with significantly lower incidence of peripheral neuropathy — the most common and treatment-limiting side effect of IV Bortezomib. The standard myeloma dose is 1.3mg/m² on days 1, 4, 8, and 11 of a 21-day cycle, typically in combination with dexamethasone and either Lenalidomide (VRd) or Cyclophosphamide (VCD).
For hospital pharmacies at Phoenix area cancer centres seeking a cost-effective supply of Bortezomib injection for their institutional formulary, Indian generic Bortenat provides USFDA-equivalent quality at significantly lower cost than the branded Velcade. Full WHO-GMP documentation and certificates of analysis are provided with every shipment.
Unnati Pharmax supplies Bortenat 3.5mg injection vials to oncology pharmacies, cancer hospitals, and distributors in Phoenix and across the USA. Visit medshopy.com or WhatsApp +91 82650 41513 for institutional pricing.
